Edgestream Partners L.P. Buys Shares of 16,725 Charles River Laboratories International, Inc. (NYSE:CRL)

Edgestream Partners L.P. purchased a new position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 16,725 shares of the medical research company's stock, valued at approximately $3,455,000.

Other institutional investors have also made changes to their positions in the company. Tortoise Investment Management LLC lifted its position in Charles River Laboratories International by 77.0% during the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company's stock worth $27,000 after acquiring an additional 57 shares during the last quarter. Headlands Technologies LLC bought a new position in shares of Charles River Laboratories International during the first quarter worth $41,000. Brown Brothers Harriman & Co. increased its stake in Charles River Laboratories International by 76.0% during the 4th quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company's stock worth $52,000 after purchasing an additional 95 shares in the last quarter. Whittier Trust Co. of Nevada Inc. lifted its holdings in shares of Charles River Laboratories International by 219.3% in the second quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company's stock valued at $58,000 after purchasing an additional 193 shares in the last quarter. Finally, Concord Wealth Partners boosted its holdings in Charles River Laboratories International by 362.5% during the first quarter. Concord Wealth Partners now owns 259 shares of the medical research company's stock worth $70,000 after purchasing an additional 203 shares during the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

CRL has been the topic of a number of recent research reports. Mizuho initiated coverage on Charles River Laboratories International in a research note on Friday, June 7th. They set a "neutral" rating and a $235.00 target price on the stock. TD Cowen reduced their price target on shares of Charles River Laboratories International from $228.00 to $203.00 and set a "hold" rating for the company in a report on Monday, August 12th. Robert W. Baird downgraded Charles River Laboratories International from an "outperform" rating to a "neutral" rating and decreased their price target for the stock from $239.00 to $191.00 in a report on Thursday, August 8th. StockNews.com upgraded shares of Charles River Laboratories International from a "hold" rating to a "buy" rating in a report on Tuesday, August 20th. Finally, The Goldman Sachs Group dropped their price target on shares of Charles River Laboratories International from $290.00 to $250.00 and set a "buy" rating on the stock in a research note on Thursday, August 8th. Ten research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $231.00.

Charles River Laboratories International Trading Down 0.1 %

Shares of NYSE:CRL traded down $0.27 during midday trading on Wednesday, hitting $205.94. 526,841 shares of the stock traded hands, compared to its average volume of 588,066. The business's 50 day moving average is $209.51 and its two-hundred day moving average is $224.67. The stock has a market capitalization of $10.61 billion, a PE ratio of 24.23, a P/E/G ratio of 3.89 and a beta of 1.36. The company has a quick ratio of 1.21, a current ratio of 1.58 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a one year low of $161.65 and a one year high of $275.00.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, August 7th. The medical research company reported $2.80 EPS for the quarter, topping analysts' consensus estimates of $2.39 by $0.41. The business had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.03 billion. Charles River Laboratories International had a net margin of 10.83% and a return on equity of 14.96%. As a group, research analysts forecast that Charles River Laboratories International, Inc. will post 10.01 earnings per share for the current year.

Charles River Laboratories International announced that its Board of Directors has initiated a stock repurchase plan on Wednesday, August 7th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the medical research company to repurchase up to 9.6% of its stock through open market purchases. Stock buyback plans are often a sign that the company's management believes its shares are undervalued.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).